French agency head quits over delayed withdrawal of slimming pill
This article was originally published in Scrip
Executive Summary
Jean Marimbert, the head of the French drug and device regulatory agency (AFSSAPS), is resigning from his post in face of growing criticism from the general public that the agency took too long to withdraw Servier's slimming drug Mediator (Benfluorex Hydrochloride) from the market. AFSSAPS, a key player in the European pharmaceutical regulatory network, suspended the marketing of Mediator in 2009.
You may also be interested in...
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.